



## Curriculum Vitae

Personal information **Katja Sliva**

### Work experience

---

1. Employer: Paul\_Ehrlich\_Institute
  - Start date: 032015
  - End date: 032023
  - Position: Quality Assessor
  - Activities: Assessment of national applications for Marketing authorisations, Assessment of applications for clinical Trials, assessment of applications for variations to Marketing authorisations, scientific advice, Assessment of decentralised Marketing applications and life cycle maintenance
  - Country: Germany
2. Employer: Paul\_Ehrlich\_Institute
  - Start date: 102008
  - End date: 022015
  - Position: Research Scientist
  - Activities: Research on Virology, Immunology, Virus\_Host\_Interactions Vaccine development Project and lab management Assessment of clinical trials Assessment of Quality
  - Country: Germany
3. Employer: Paul\_Ehrlich\_Institute
  - Start date: 102006
  - End date: 102008
  - Position: Post\_Doctoral Fellow
  - Activities: Reserach on Virology, Poxviruses Vaccine development Cell biology Immunology
  - Country: Germany

### Education and training

---

1. Subject: Goethe\_University Frankfurt am Main / Georg\_Speyer\_Haus Frankfurt am Main
  - Start date: 042003
  - End date: 092006
  - Qualification: PhD in Biology (Virology)
  - Organisation: Gene Therapy, Cancer, Cell biology, Molecular biology, Virology, shRNA
  - Country: Germany
2. Subject: Goethe\_University Frankfurt am Main
  - Start date: 1998
  - End date: 2002
  - Qualification: Diploma in Biology
  - Organisation: Human Genetics, Anthropology, Psychology, Microbiology
  - Country: Germany
3. Subject: Technical University Darmstadt
  - Start date: 1996
  - End date: 1998
  - Qualification: Undergraduate studies \_ Pre\_Diploma
  - Organisation: Genetics, Microbiology, Mathematics, Physics, (Bio\_)Chemistry, Plantphysiology, Molecular Biology
  - Country: Germany

### Additional information

---

#### Publications

Büchner SM, Sliva K, Bonig H, Völker I, Waibler Z, Kirberg J, Schnierle BS (2013). Delayed onset of graft\_versus\_host disease in immunodeficient human leucocyte antigen\_DQ8 transgenic, murine major histocompatibility complex class II deficient mice repopulated by human peripheral blood mononuclear cells. Clin Exp Immunol. 2013 Aug;173(2):355\_64. Kraus B, Fischer K, Büchner SM, Wels WS, Löwer R, Sliva K, Schnierle BS (2013). Vaccination directed against the human endogenous retrovirus\_K envelope protein inhibits tumor growth in a murine model system. PLoS One. 2013 Aug 30;8(8):e72756. Kraus B, Mönk B, Sliva K, Schnierle BS (2012). Expression of human endogenous retrovirus\_K coincides with that of micro\_RNA\_663 and \_638 in germ\_cell tumor cells. Anticancer research, Nov;32(11):4797\_804 Sliva K, Resch T, Kraus B, Goffinet C, Keppler OT, Schnierle BS (2012). The cellular antiviral restriction factor tetherin does not inhibit poxviral replication. Journal of Virology, Feb;86(3):1893\_6. Schaser T, Wrede C, Duemer L, Sliva K, Cichutek K, Schnierle B, Buchholz CJ (2011). RNAi mediated gene silencing in tumour tissue using replication\_competent retroviral vectors. Gene Therapy, Oct;18(10):953\_60. Sliva K. and Schnierle BS (2010). Selective gene silencing by viral delivery of short hairpin RNA. Virology Journal, Sep 21;7:248. Zwilling J., Sliva K., Schwantes A., Schnierle B., Sutter G (2010). Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus\_induced cell motility but not growth in human and murine cells. Virology, Sep 1;404(2):231\_9. Kremer M., Sliva K., Klemke CD, Schnierle BS (2010). Cutaneous T\_cell lymphoma cells are sensitive to rapamycin. Experimental Dermatology, Jul 14 Lantermann M., Schwantes A., Sliva K., Sutter G., Schnierle BS (2007). Vaccinia virus double\_stranded RNA\_binding protein E3 does not interfere with siRNA mediated gene silencing in mammalian cells. Virus Research, Feb 13 Sliva K. and Schnierle BS (2007). From actually toxic to highly specific \_ novel drugs against poxviruses. Virology Journal, Jan 15;4:8 Sliva K. and Schnierle BS (2006). Stable integration of a functional shRNA expression cassette into the murine leukaemia virus genome. Virology Jul 20;351(1):218\_25 Sliva K., Erlwein O., Bittner A., Schnierle BS (2004). Murine leukemia virus (MLV) replication monitored with fluorescent proteins. Virology Journal, Dec 20;1:14 Sliva K. and Schnierle BS

(2004). Targeting retroviral vector entry by host range extension. Gene Therapy and Molecular Biology 8: 335\_342

Projects

Memberships CTS WP

Other Relevant Information